Figure 1From: Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer Serum sTRAIL levels. No difference between two groups (P = 0.50) before bevacizumab treatment: 1.12 ± 0.04 ng/ml in metastatic colon cancer patients and 1.17 ± 0.08 ng/ml in healthy control individuals.Back to article page